Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793245 | 0.86 | POLB (0.88) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL421626 | 0.82 | USP2 (0.63) | POLBLMNAGAAKMT2AMEN1 | |
| SCHEMBL1229961 | 0.82 | USP2 (0.69) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL12793258 | 0.81 | POLB (1.00) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL5960399 | 0.81 | POLB (0.80) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL76639 | 0.81 | USP2 (0.73) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL2122633 | 0.81 | USP2 (0.73) | POLBLMNASMN1; SMN2GAAKMT2A | |
| Water SCHEMBL28009498 | 0.80 | POLB (0.71) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL1419418 | 0.80 | POLB (0.56) | POLBLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL8871272 | 0.79 | POLB (0.76) | POLBLMNASMN1; SMN2GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| CN-110546140-A | selective HDAC6 inhibitors | ITALFARMACO SPA | 2019-12-06 | — | — | CN | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| WO-2018042377-A1 | NOVEL INDAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-03-08 | — | — | WO | claimed |
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE UNIVERSITY OF CHICAGO (US) | 2017-09-28 | — | — | US | claimed |
| US-9675592-B2 | Methods and compositions for bacteria infections | THE UNIVERSITY OF CHICAGO (US) | 2017-06-13 | — | — | US | claimed |
| CN-105980386-A | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2016-09-28 | — | — | CN | claimed |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-05 | — | — | US | claimed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1064274-A1 | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | AstraZeneca AB (SE) | 2001-01-03 | — | — | EP | claimed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
| WO-1999047508-A1 | BENZENESULFONAMIDE-DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 1999-09-23 | — | — | WO | claimed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | claimed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273954-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | POLB 90/4885LMNA 1893/4885SMN1; SMN2 1662/4885 |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | POLB 2395/4885LMNA 2737/4885SMN1; SMN2 1532/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | POLB 1093/4885LMNA 1241/4885SMN1; SMN2 869/4885 |
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | POLB 4326/4885LMNA 1603/4885SMN1; SMN2 3038/4885 |
| US-20160120852-A1 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS | SPOUT1, OXA1L, VSIR | POLB 90/4885LMNA 1893/4885SMN1; SMN2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.